Related references
Note: Only part of the references are listed.Vertebral fracture assessment using a semiquantitative technique
Harry K. Genant et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy
Jean-Yves Reginster et al.
BONE (2008)
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
An approach for identifying postmenopausal women age 50-64 years at increased short-term risk for osteoporotic fracture
Y.-T. Chen et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Prediction of bone loss using biochemical markers of bone turnover
J. Lenora et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate
Michael McClung et al.
BONE (2007)
Osteopenia
Sundeep Khosla et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study
P. Garnero et al.
BONE (2007)
Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: Sequential triple biopsy studies with micro-computed tomography
B Borah et al.
BONE (2006)
Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene
Michael R. McClung et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2006)
Identification of osteopenic women at high risk of fracture: The OFELY study
E Sornay-Rendu et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Does osteopenia warrant treatment?
JA Simon
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2005)
Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women
JT Schousboe et al.
ANNALS OF INTERNAL MEDICINE (2005)
Hip fracture in women without osteoporosis
SA Wainwright et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Incidence of vertebral deformities in 255 female rheumatoid arthritis patients measured by morphometric X-ray absorptiometry
RE Orstavik et al.
OSTEOPOROSIS INTERNATIONAL (2005)
An investigation of the predictors of bone mineral density and response to therapy with alendronate in osteoporotic men
WM Drake et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
IR Reid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women - Results from the National Osteoporosis Risk Assessment
ES Siris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women
GY Boivin et al.
BONE (2000)
Biochemical markers as predictors of rates of bone loss after menopause
A Rogers et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
Share Paper
